Advertisement

Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment

Published:September 09, 2016DOI:https://doi.org/10.1016/j.jtho.2016.08.144

      Abstract

      Introduction

      Osimertinib is an EGFR inhibitor licensed for the treatment of EGFR-mutant, T790M-positive NSCLC. Previously unreported, frequent transient asymptomatic pulmonary opacities were noted in patients during osimertinib therapy at the University of Colorado.

      Methods

      Computed tomography imaging and clinical notes on patients with NSCLC who had been treated with osimertinib at the University of Colorado were retrospectively reviewed.

      Results

      Transient asymptomatic pulmonary opacities developed in seven of 20 patients (35%) while they were receiving osimertinib. The radiological patterns seen included ground-glass opacities with or without nodular consolidation. The median time to development of the first lesion was 8.7 weeks (range 1.6–43 weeks), the median time to resolution during continued osimertinib was 6 weeks (range 1–11 weeks).

      Conclusions

      Transient asymptomatic pulmonary opacities may be a previously unrecognized, benign feature associated with osimertinib therapy that may be mistaken for isolated pulmonary progression or the beginning of more severe pneumonitis. If new-onset pulmonary lesions, especially those associated with ground-glass appearances, are asymptomatic and localized and there is no evidence of disease progression elsewhere, it may be reasonable to continue treatment with osimertinib and monitor the lesions for resolution.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Thoracic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hong D.
        • Zhang G.
        • Zhang X.
        • Lian X.
        Pulmonary toxicities of gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
        Medicine (Baltimore). 2016; 95: e3008
        • Cohen M.H.
        • Williams G.A.
        • Sridhara R.
        • Chen G.
        • Pazdur R.
        FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
        Oncologist. 2003; 8: 303-306
        • Travis W.D.
        • Costabel U.
        • Hansell D.M.
        • et al.
        An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
        Am J Respir Crit Care Med. 2013; 188: 733-748
        • Macerelli M.
        • Caramella C.
        • Faivre L.
        • et al.
        Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?.
        Lung Cancer. 2014; 83: 383-388
        • Camus P.
        • Kudoh S.
        • Ebina M.
        Interstitial lung disease associated with drug therapy.
        Br J Cancer. 2004; 91: S18-S23
        • Jänne P.A.
        • Yang J.C.-H.
        • Kim D.-W.
        • et al.
        AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
        N Engl J Med. 2015; 372: 1689-1699
        • Nie K.K.
        • Zou X.
        • Geng C.X.
        • Zhang L.
        • Liu S.C.
        • Zhang C.L.
        • Ji Y.X.
        AZD9291-induced acute interstitial lung disease.
        Chin Med J. 2016; 129: 1507-1508